Two Decades of Neurosurgical Device Innovation: A Comprehensive Analysis of FDA Authorization Trends From 7800 Approvals by Subspecialty, Regulatory Pathway, and Approval Time
Authors:
- Arjun K. MentaArjun K. Menta
- Andrew M. HershAHAndrew M. Hersh
- Patrick KramerPKPatrick Kramer
- Tej D. AzadTATej D. Azad
- Brendan JudyBJBrendan Judy
- Ryan P. LeeRLRyan P. Lee
- April Zambelli-WeinerAZApril Zambelli-Weiner
- Youseph YazdiYYYouseph Yazdi
- Alexander A. KhalessiAKAlexander A. Khalessi
- Nicholas TheodoreNTNicholas Theodore
- 3 November 2026
- journal article
- Published by Wolters Kluwer Health in Neurosurgery
Abstract
BACKGROUND AND OBJECTIVES: Technological progress has accelerated neurosurgical care, yet a panoramic view of these innovations remains lacking. This study aims to analyze all US Food and Drug Administration (FDA) authorizations issued from 2000 to 2023 to map neurosurgical device output by subspecialty, compare regulatory pathways and approval times, and identify factors affecting market entry. METHODS: All devices cleared or approved by the FDA Neurology and Orthopedic Review Panels (January 2000-December 2023) were extracted from publicly available 510(k), De Novo, Humanitarian Device Exemption, and Premarket Approval databases. Devices were assigned to 1 of 9 neurosurgical subspecialties and stratified by regulatory pathway, device class, company maturity, and geographic origin. Descriptive statistics, analysis of variance, and Welch t -tests assessed temporal and categorical differences. RESULTS: Of 16 064 devices reviewed by the FDA Neurology and Orthopedic panels, 7873 (49.0%) were neurosurgical, rising 172.1% over the period. Spine and peripheral nerve (5227 devices) and stereotactic and functional (1378) dominated volume and number of new market entries, while cerebrospinal fluid disorders (n = 149) and cranial trauma (n = 111) had fewer approvals. Cerebrovascular and endovascular (95.5%) and cranial trauma (200.0%) showed the largest growth rates, while cerebrospinal fluid disorders (−54.2%) and general cranial surgery (−34.5%) declined over time. Mean approval time varied by subspecialty ( P < .001), the shortest for spine and peripheral nerve (119.0 ± 102.7 days) and the longest for stereotactic and functional (158.7 ± 121.5 days). Approval or clearance times were strongly influenced by regulatory pathway and device class (both P < .001), with Premarket Approval devices (584.8 ± 323.3 days) the longest. Mature companies achieved faster approvals compared with startups (114.9 ± 97.0 vs 174.5 ± 133.9 days, P < .001). CONCLUSION: Neurosurgical device output has more than doubled, but volume concentrates where predicates are rich and reimbursement established, not where clinical need or novelty is the greatest. Pathway architecture, device complexity, and sponsor experience influence approval efficiency more than novelty.Keywords
This publication has 18 references indexed in Scilit:
- Urologic Device Innovation and Trends: An Analysis of Food and Drug Administration Approvals From 1990 to 2023Urology Practice, 2026
- Sonolucent Cranioplasty for Transcranial Ultrasonographic ImagingJAMA Surgery, 2025
- Enabling Technologies in the Management of Cervical Spine TraumaClinical Spine Surgery, 2024
- Innovations in Spine Surgery: A Narrative Review of Current Integrative TechnologiesWorld Neurosurgery, 2023
- Time From Authorization by the US Food and Drug Administration to Medicare Coverage for Novel TechnologiesJAMA Health Forum, 2023
- FDA Regulation and Approval of Medical Devices: 1976-2020JAMA, 2021
- Innovations in Functional Neurosurgery and Anesthetic ImplicationsJournal of Neurosurgical Anesthesiology, 2018
- Overview of the US FDA Medical Device Approval ProcessCurrent Cardiology Reports, 2014
- FDA Authorization of Medical DevicesJAMA, 2014
- The 510(k) Ancestry of a Metal-on-Metal Hip ImplantNew England Journal of Medicine, 2013